Enhanced Commercial Focus Leads to Rebound in Stage One Surgeries in the US
Second quarter 2024/25 (August – October) · Net sales amount to 21.8 (27.6) MSEK, which is a decrease of 21.0 % compared with the corresponding period last year. The growth in the US market and in Rest of the World is -23 % and -14 % compared with the corresponding period last year, respectively. · Operating result amounts to -11.3 (6.5) MSEK. The operating result amounted to -10.5 MSEK excluding currency effects of -0.8 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to -8.9 (3.9) MSEK, which resulted in earnings per share of SEK -0.46 (-0.22). · Cash flow from operating activities amounts to -9.5 MSEK (6.8), change in working capital was 1.0 MSEK (-1.2) and investing activities -3.3 (-2.0). Total cash flow was -12.0 (3.4) MSEK. Liquid assets as of 2024-10-31 amount to 34.1 (33.3) MSEK, not including 31.6 MSEK in accounts receivables. Significant events in the quarter · The board announced that Scott Flora, board member since 2023, was appointed acting CEO of Integrum AB after Rickard Brånemark left the role and was appointed Chief Scientific Advisor. · The first OPRA® Implant System procedure was done in the UK. · Ty Hanners was appointed Director of Sales, US, focused on expanding the OPRA surgical system product offering to amputees. 1 May 2024 – 31 October 2024 (6 months) · Net sales amounted to 40.2 (48.0) MSEK, a decrease of 16.1 % compared with the corresponding period in the previous year. The growth in the US market and in the Rest of the World is -11.4 % and -16.5 % compared with the corresponding period last year, respectively. · Operating result amounted to -23.2 (3.5) MSEK. The operating result amounted to -21.1 MSEK excluding currency effects of -2.1 MSEK, most of which are unrealized internal accounts receivables. · Profit after tax amounted to -18.4 (1.0) MSEK, which resulted in earnings per share of SEK -0.95 (0.06). · Cash flow from operating activities amounts to -20.0 (4.2) MSEK. Total cash flow was 17.2 (-8.6) MSEK. Significant events in the year · Integrum carried out an issue of 961,539 new series B shares, at a subscription price of SEK 52 per share, raising proceeds of approximately SEK 50 million. · The company has finalized a trade term loan facility agreement of about 24 MSEK as an option to finance its accounts receivables · Integrum announced that the company has received market approval for the OPRA® Implant System in Israel.
read moreIntegrum AB: Invitation to the Second Quarter 2024/25 Results Presentation
Mölndal, Sweden – November 29, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2024/25 results on December 4, 2024 at 14:00 CEST.
read moreIntegrum Launches Service Initiative to Strengthen U.S. Market Growth
Integrum AB (publ), ticker INTEG, a leader in medical technology and developer of the bone-anchored OPRA® Implant System, announces the launch of a new service initiative to enhance warranty and service support for its Axor™ II devices. This initiative is a critical step in advancing Integrum’s expansion in the U.S. market and driving sustainable growth.
read moreOsseointegration for Amputees Makes its Education Forum Debut at OTA 2024
Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA® Implant System to amputees announces its education forum debut.
read moreTy Hanners appointed Director of Sales, US, focused on OPRA Implant System for Amputees
Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, announces that Ty Hanners has been appointed Director of Sales, US, focused on expanding the OPRA surgical system product offering to amputees. He will start on October 14, 2024.
read moreJoin Us for an Investor Update Online with our Acting CEO Scott Flora
Integrum AB (publ), the medical technology company that improves the lives of amputees, cordially invites you to an online investor information session on September 25, 2024, @ 3 pm CEST.
read moreInger Rydin is appointed interim COO and takes office immediately
Integrum AB (publ), the medical technology company that improves the lives of amputees, announces that Inger Rydin has been appointed interim COO and will be responsible for operations at the office in Mölndal, Sweden. Inger, who served as interim COO at Integrum from 2021 to 2023, will be part of the management team. She takes office immediately.
read moreThe board of Integrum appoints Scott Flora as acting CEO
Integrums CEO Rickard Brånemark has today agreed together with the board that he will leave the CEO role. The board announces that Scott Flora, board member since 2023, has been appointed acting CEO of Integrum AB. He takes office with immediate effect. The board will immediately start the recruiting process of a new CEO. Rickard Brånemark is appointed Chief Scientific Advisor.
read moreFocus on long-term growth creates setback in sales
FIRST QUARTER 2024/25 (MAY – JULY) · Net sales amounted to 18.5 (20.4) MSEK, which is a decrease of 9.5% compared with the corresponding period last year. · Operating profit amounted to -12.0 (-2.9) MSEK. The operating result amounted to -10.6 MSEK excluding currency effects of -1.4 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to -9.4 (-2.9) MSEK, which resulted in earnings per share of SEK -0.49 (-0.1). · Cash flow from operating activities amounts to -10.5 MSEK (-2.6), change in working capital was -3.5 MSEK (-7.1) and investing activities -2.6 (-1.9). Total cash flow was 29.3 (-12.1) MSEK. Liquid assets as of 2024-07-31 amount to 46.2 (29.9) MSEK, not including 33.7 MSEK in accounts receivables. Significant events in the quarter · Integrum entered a commercial collaboration and distribution agreement with Hanger, the leading provider of amputee care and prosthetics in the US that delivers care to almost one-third of all amputees in the country. · Integrum carried out an issue of 961,539 new series B shares, at a subscription price of SEK 52 per share, raising proceeds of approximately SEK 50 million. · The company has finalized a trade term loan facility agreement of about 24 MSEK as an option to finance its accounts receivables. · The company signed a Memorandum of Understanding with Coapt LLC, with the intention to provide Integrum the possibility to combine Coapt’s pattern recognition technology with the continued development of e-OPRA® Implant System. · Integrum announced that the company has received market approval for the OPRA® Implant System in Israel.
read moreIntegrum AB: Invitation to the First Quarter 2024/25 Results Presentation
Mölndal, Sweden – August 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its first quarter 2024/25 results on August 29, 2024 at 14:00 CEST.
read moreIntegrum has carried out a directed new issue of 961,539 series B shares, raising proceeds of approximately SEK 50 million
Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) has successfully carried out an issue of 961,539 new series B shares, at a subscription price of SEK 52 per share, raising proceeds of approximately SEK 50 million (the “Directed Issue”).
read moreIntegrum intends to carry out a directed new issue of series B shares of approximately SEK 50 million
Mölndal, Sweden – 13 June 2024 – Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) (“Integrum” or the “Company”) announces its intention to carry out an issue of series B shares of approximately SEK 50 million directed to Swedish and international institutional investors (the “Directed Issue”). Integrum has appointed Carnegie Investment Bank AB (publ) (“Carnegie”) as Sole Global Coordinator and Bookrunner to explore the conditions to carry out the Directed Issue through an accelerated book-building procedure.
read moreIntegrum signs Memorandum of Understanding with Coapt for the use of its pattern recognition technology with the e-OPRA[TM] Implant System
Mölndal, Sweden – June 13, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a Memorandum of Understanding with the American medtech company Coapt LLC, with the intention to provide Integrum the possibility to combine Coapt’s pattern recognition technology with the continued development of e-OPRA[TM] Implant System.
read moreIntegrum enters collaboration and distribution agreement with Hanger – the leading provider of amputee care and prosthetics in the US
Mölndal, Sweden – June 10, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has entered a commercial collaboration and distribution agreement with Hanger, the leading provider of amputee care and prosthetics in the US that delivers care to almost one-third of all amputees in the country. Within the framework of the agreement, Integrum’s prosthetic product portfolio will be made available to eligible patients at any of Hanger Clinic’s 900 patient care facilities nationwide as well as distributed to other facilities. The agreement will take effect on June 10, 2024.
read moreA Record Year in Sales
FOURTH QUARTER 2023/24 (FEBRUARY – APRIL) · Net sales amount to 26.1 (18.1) MSEK, which is an increase of 43.7% compared with the corresponding period last year. The growth in the US market and in Rest of the World is 15.1% and 147 % compared with the corresponding period last year, respectively. · Operating result amounts to 2.6 (-7.2) MSEK (EBIT 10.1%). The operating result amounted to -1.8 MSEK (EBIT -7.0%) excluding currency effects of 4.5 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounted to 2.3 (-6.1) MSEK, which resulted in earnings per share of SEK 0.1 (-0.33). · Cash flow from operating activities amounts to 2.8 MSEK (-6.4), change in working capital was -10.2 MSEK (3.8) and investing activities -3.7 (-1.7). Total cash flow was -11.5 (-4.4) MSEK. Liquid assets as of 2024-04-30 amount to 16.9 (41.9) MSEK, not including 33.6 MSEK in accounts receivables. Significant events in the quarter · Independent researchers published an article showing that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times while simultaneously improving quality of life. · Integrum also announced that the company has entered distribution agreements in Israel and in the UK. Significant events after the quarter · The company has extended its credit facility and is finalizing a factoring setup, which together will make another 30 MSEK available to support expansion. 1 MAY 2023 – 30 APRIL 2024 (12 MONTHS) · Net sales amounted to 104.1 (74.3) MSEK, an increase of 40.2% compared with the corresponding period in the previous year. The growth in the US market and in Rest of the World is 25% and 95% compared with the corresponding period last year, respectively. · Operating result amounted to 6.5 (-19.7) MSEK. The operating result amounted to 0.7 MSEK (EBIT 0.7%) excluding currency effects of 5.8 MSEK, most of which are unrealized internal accounts receivables. · Profit after tax amounted to 4.2 (-16.2) MSEK, which resulted in earnings per share of SEK 0.2 (-0.9). · Cash flow from operating activities amounts to 8.0 (-20.6) MSEK. Total cash flow was -25.0 (-33.4) MSEK. Significant events in the year · Integrum appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan. Jeff has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. · In Q2, The Centers for Medicare and Medicaid Services (CMS) granted the external prosthetic connection device Axor II™ a new reimbursement code. The new code is connected to a set reimbursement that will help to drive growth in the US. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss. · Also during the year, the company entered into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.
read moreIntegrum receives market approval for OPRA[® in Israel]
Mölndal, Sweden – May 29, 2024 - Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has received market approval for the OPRA[®] Implant System in Israel.
read moreIntegrum AB: Invitation to the Fourth Quarter 2023/24 Results Presentation
Mölndal, Sweden – May 24, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its fourth quarter 2023/24 results on May 30, 2024 at 14:00 CEST.
read moreIntegrum has been granted a registered trademark for OPRA® Implant System in the EU
Mölndal, Sweden – May 15, 2024 — Integrum (publ) (Nasdaq First North Growth Marketing: INTEG B) announces that the European Union Intellectual Property Office, EUIPO, has approved Integrum’s product registration application for the OPRA® Implant System.
read moreIntegrum launches short video documentary to showcase the company’s efforts to treat combat amputees in Ukraine
Mölndal, Sweden – May 3, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has launched a short video documentary about the company’s Center of Excellence in Kyiv, Ukraine. During Dr Rickard Brånemark’s latest training session at the end of April, the center was visited by several delegations with politicians, company leaders and military representatives, and the video documentary was screened to introduce discussions on the future of trauma healthcare in Ukraine. Among the visitors were the Swedish Minister for Social Services, Camilla Waltersson Grönvall.
read moreIntegrum expands its product offering to the United Kingdom market
Mölndal, Sweden – May 2, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with LEDA Orthopaedics Ltd., a local medical device distributor specialized in niche trauma implants, hand surgery prostheses and unique solutions for orthopaedic procedures, to introduce OPRA[TM] Implant System in the United Kingdom.
read moreIntegrum expands its product offering into the Israeli market
Mölndal, Sweden – March 26, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company has entered a commercial agreement with AMI Technologies, a leading local medical device distributor, to introduce the OPRA[TM] Implant System in Israel.
read moreHealth economic study shows positive outcome using Integrum’s OPRA[TM] Implant System over socket prostheses in transfemoral amputees
Mölndal, Sweden – March 19, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that a team of independent researchers, from six prestigious academic and clinical institutions in the US, have published a health economic article analyzing potential effects on societal cost-control and quality-of-life when utilizing osseointegrated transfemoral prostheses compared to traditional socket prostheses. The study’s meta-analyses show that costs associated with maintaining functional socket prosthesis usage exceed those of using osseointegration alternatives several times while simultaneously improving quality of life. The article will be featured in the March 2024 issue of Bone & Joint Open.
read moreA new record revenue quarter with 61% growth
THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of SEK 0.05 (-0.74). · Cash flow from operating activities amounts to 2.0 MSEK (-14.1), change in working capital was -2.9 MSEK (8.2) and investing activities -4.0 (-1.2). Total cash flow for the period was -5.0 (-7.1) MSEK. Liquid assets as of 2024-01-31 amount to 28.4 (46.3) MSEK, not including 29.2 MSEK in accounts receivables. Significant events in the third quarter · The US Department of Defense decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. The study will be performed by the Walter Reed National Military Medical Center. Integrum will supply OPRA™ Implant Systems on commercial terms. · The company held a pre-submission meeting with the US Food and Drug Administration (FDA). Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application for Integrum’s OPRA™ Implant System in transhumeral amputations based on existing clinical data. · Integrum received its final MDR certification. The company’s OPRATM Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.
read moreCORRECTION A new record revenue quarter with 61% growth
The figures for Rights of Use assets (6,620 KSEK) were missing in the previous report and have now been added. The total sums for Fixed Assets and the Balance Sheet remain the same. THIRD QUARTER 2023/24 (NOV – JAN) · Net sales amounts to 30.1 (18.7) MSEK, which is an increase of 61% compared with the corresponding period last year. The growth in the US market is 43% compared with the corresponding period last year. · Operating profit amounts to 0.3 (-13.8) MSEK (EBIT 1.1%). The operating profit amounted to 6.1 MSEK (EBIT 20.2%) excluding currency effects of -5.7 MSEK, most of which are unrealized internal accounts receivables. · Profit/loss after tax amounts to 0.8 (-13.6) MSEK, which resulted in profit per share of SEK 0.05 (-0.74). · Cash flow from operating activities amounts to 2.0 MSEK (-14.1), change in working capital was -2.9 MSEK (8.2) and investing activities -4.0 (-1.2). Total cash flow for the period was -5.0 (-7.1) MSEK. Liquid assets as of 2024-01-31 amount to 28.4 (46.3) MSEK, not including 29.2 MSEK in accounts receivables. Significant events in the third quarter · The US Department of Defense decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. The study will be performed by the Walter Reed National Military Medical Center. Integrum will supply OPRA™ Implant Systems on commercial terms. · The company held a pre-submission meeting with the US Food and Drug Administration (FDA). Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application for Integrum’s OPRA™ Implant System in transhumeral amputations based on existing clinical data. · Integrum received its final MDR certification. The company’s OPRATM Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss. · The company established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.
read moreIntegrum AB: Invitation to the Third Quarter 2023/24 Results Presentation
Mölndal, Sweden – February 23, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its third quarter 2023/24 results on February 29, 2024 at 14:00 CEST.
read moreIntegrum has sold and delivered OPRA[TM] Implant Systems to a value of SEK 3.5 million to Center of Excellence in Ukraine
Mölndal, Sweden – January 31, 2024 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces that the company today has sold and delivered OPRA™ Implant Systems to a value of SEK 3.5 million to Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, Ukraine.
read moreIntegrum establishes Center of Excellence in Ukraine
Mölndal, Sweden – December 20, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has established a Center of Excellence at the Center for Complex Endoprosthetics, Osseointegration and Bionics in Kyiv, with the intention to spearhead orthopedic treatment using OPRA™ Implant System in individuals who have suffered limb loss.
read moreIntegrum’s MDR certification is completed for the OPRA[TM] Implant System
Mölndal, Sweden – December 15, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has received its final MDR certification, thus finalizing the review process of the company’s products under the new EU medical device regulatory (MDR) framework. The company’s OPRA[TM] Implant System product portfolio has thereby been granted MDR certification and may be freely distributed within the EU for treatment in individuals living with disabilities because of limb loss.
read moreRecord sales and profitability
SECOND QUARTER 2023/24 (MAY – JULY) · Net sales amounted to SEK 27.6 (20.2) million, which is an increase of 36% compared with the corresponding period last year. The growth in the US market is 27% compared with the corresponding period last year. · Operating profit amounted to SEK 6.5 (0.9) million. Excluding direct currency effects, the operating profit is at 3.8 MSEK (-5.2). · Profit/loss after tax amounted to SEK 3.9 (2.3) million, which resulted in earnings per share of SEK 0.21 (0.13). · Cash flow from operating activities amounted · to SEK 6.8 (-5.3) million. Liquid assets as of 2023-10-31 amounted to SEK 33.3 (53.4) million. Significant events in the quarter · In the quarter, The Centers for Medicare and Medicaid Services (CMS) granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code is connected to a set reimbursement that will help to drive growth in the US. · The company appointed Alex Winber as Vice President Sales and Marketing with full focus on the US. The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US. · The Board of Directors initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™ Implant System. · The company received a Unitary Patent approval pertaining to NeuromotusTM. The patent grants immediate proprietary rights to Integrum in 17 separate European countries. · During the quarter, the company entered into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon. · In the period, Scott Flora was elected as full member of the company’s board at the annual general meeting. · CEO Rickard Brånemark moderated a workshop in Ukraine on 21 September, focusing on war-related amputee care. Also he visited Kyiv, Ukraine, to treat wounded soldiers, to train Ukrainian orthopaedic surgeons in advanced amputee care and to support the build-up of expanded trauma healthcare. 1 MAY – 31 OCTOBER 2023/24 (6 MONTHS) · Net sales amounted to SEK 48.0 (37.5) million, which is an increase of 28% compared with the corresponding period last year. The growth in the US market is 22% compared with the corresponding period last year · Operating profit amounted to SEK 3.5 (1.2) million. · Profit/loss after tax amounted to SEK 1,2 (1.8) million, which resulted in earnings per share of SEK 0,06 (0.1). · Cash flow from operating activities amounted to SEK 4.2 (-11.5) million. · Integrum announced that Shirley Ryan AbilityLab has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.
read moreIntegrum AB changes Certified Adviser to Carnegie Investment Bank AB (publ)
Mölndal, Sweden – November 30, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces a change of Certified Adviser from Erik Penser Bank AB to Carnegie Investment Bank AB (publ).
read moreIntegrum AB: Invitation to the Second Quarter 2023/24 Results Presentation
Mölndal, Sweden – November 28, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host a webcast presentation of its second quarter 2023/24 results on December 4, 2023 at 14:00 CEST.
read moreIntegrum plans to submit a PMA application to the FDA for the use of OPRA in transhumeral amputations based on existing clinical data
Mölndal, Sweden – November 13, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has held a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss the regulatory pathway for the use of Integrum’s OPRA™ Implant System in transhumeral amputations. Based on the conclusions from the meeting, Integrum plans to submit a Pre-Market Approval (PMA) application based on existing clinical data.
read moreClinical study of Integrum’s OPRA™ Implant System on below-knee amputations will include up to 30 patients and is fully funded by the Department of Defense
Mölndal, Sweden – November 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the US Department of Defense has decided to fully fund a clinical study of OPRA™ Implant System on up to 30 patients with transtibial (below-knee) amputations. As previously announced, the study will be performed by the Walter Reed National Military Medical Center in Bethesda, Maryland. Integrum will supply OPRA™ Implant Systems to Walter Reed on commercial terms.
read moreCorrection missing MAR reference: Integrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023
Mölndal, Sweden – November 10, 2023 — For technical and administrative reasons, the previous press release was missing the appropriate MAR reference which is now added. All other items remain the same. Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.
read moreIntegrum publishes preliminary revenue, result and and cash flow figures for Q2, 2023
Mölndal, Sweden – November 9, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that it expects its revenue, operating profit and cash flow for Q2 will be higher than the market expectations.
read moreIntegrum’s OPRA™ Implant System gets FDA approval for clinical study on below-knee amputations
Mölndal, Sweden – October 30, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company’s OPRA™ Implant system is approved by FDA to be used in a clinical study on below-knee amputations in the US
read moreIntegrum moves into Turkey
Mölndal, Sweden – October 27, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company is entering into the Turkish market with the OPRA™ Implant system in collaboration with the distributor Medikon.
read moreIntegrum announces the world’s first long-term integrated bionic hand enriched with motor and sensory AI
Mölndal, Sweden, October 12, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the long-term follow-up of a patient who received a human-machine bionic hand prosthesis, utilizing the company’s innovative implantable solution, has shown successful results. The groundbreaking system represents a future standard of advanced prosthetic solutions.
read moreIntegrum receives a Unitary Patent for Neuromotus in the EU
Mölndal, Sweden, October 10, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has received a Unitary Patent approval pertaining to Neuromotus[TM] – a clinical innovation aimed at treating patients suffering from Phantom Limb Pain. The new patent process, which was installed by the EU in June 2023, grants immediate proprietary rights to Integrum in 17 separate European countries.
read moreIntegrum welcomes Scott Flora as full board member
Mölndal, Sweden – October 10, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that Scott Flora was recently elected as full member of the company’s board at the annual general meeting.
read moreIntegrum attends international expert workshop on osseointegration and bionic limb reconstruction
Mölndal, Sweden, September 27, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company is attending an international meeting and workshop event gathering experts in the field of osseointegration and bionic limb reconstruction, at the prestigious Rizzoli Orthopaedic Institute at the University of Bologna, Italy, on October 18–19[th].
read moreIntegrum participates in war-related amputee care workshop to support amputee care in Ukraine
Mölndal, Sweden, September 19, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company’s CEO Rickard Brånemark will moderate a workshop in Ukraine on 21 September, focusing on war-related amputee care. The workshop gathers some of the world's most prominent specialists and is supported by several ministries in Ukraine.
read moreIntegrum initiates a strategic review process to accelerate growth
Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that its Board of Directors has initiated a review and evaluation of strategic alternatives to further accelerate the global roll-out of its unique OPRA™ Implant System.
read moreIntegrum announces organizational changes and appoints Alex Winber as VP Sales and Marketing in the US
Mölndal, Sweden, September 11, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) announces today that the company has appointed Alex Winber as Vice President Sales and Marketing with full focus on the US. The appointment is part of restructuring the company's sales and marketing organization, focusing on executing growth in the US.
read moreIntegrum receives reimbursement code for Axor II™
Mölndal, Sweden, September 08, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that The Centers for Medicare and Medicaid Services (CMS) have granted the osseointegrated external prosthetic connection device Axor II™ a new reimbursement code. The new code, which is expected to take effect in October, is connected to a set reimbursement that will help to drive growth in the US.
read moreIntegrum reports highest quarterly sales revenue ever
FIRST QUARTER 2023/24 (MAY – JULY) · Net sales amounted to SEK 20.4 (17.2) million, which is an increase of 18% compared with the corresponding period last year. · Operating profit amounted to SEK -2.9 (0.4) million. Excluding one-off costs the operating profit is SEK 0.5 million. The largest such cost is severance pay regarding the change of leadership in the US. · Profit/loss after tax amounted to SEK -2.9 (-0.6) million, which resulted in earnings per share of SEK -0.1 (-0.03). · Cash flow from operating activities before changes in working capital amounted to SEK -2.6 (-0.3) million. · Liquid assets as of 31 July 2023 amounted to SEK 29.9 (57.3) million. Although Q1 saw a negative cash flow overall, the largest effect comes from increase in receivables, and with SEK 23,3 million in total AR, it reinforces the management position that the business has the liquid assets needed for further growth. · Currency fluctuations continue to affect the company operating profit. During the quarter the operating result was positively affected with 2,4 MSEK from currency effect on intragroup Accounts receivables (AR). Significant events in the quarter · Integrum appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan. Jeff has more than 20 years of success in the surgical and medical device industry and has a proven track record of successfully developing and leading highly effective sales teams. He started his position in July. · In May, Scott Flora was appointed adjunct board member. He brings extensive global business competence in orthopaedics. · The academic evaluation of a scientific paper on sensory feedback using the OPRA[TM] Implant System together with e-OPRA[TM] confirmed that no misconduct had been committed. · Integrum announced that Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago, US – has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.
read moreInstructional Course: OPRA™ Implant System
The course will be held, live and in person, in Gothenburg, Sweden, on Sept 28th 2023. Please note, the deadline for registration is Sept 12th. Meeting address GoCo House (conference room: Marie Curie), Entreprenörsstråket 10, 431 53 Mölndal, Sweden Time Sept 28th, 8:45-17:00 CET Key Speakers Final program will be sent 2 weeks prior to […]
read moreIntegrum’s technology using AI gives an above-elbow amputee unprecedented control of every finger in a bionic hand
Mölndal, Sweden, July 13, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the first case study of a person with above-elbow amputation obtaining unprecedented control of every finger in a bionic hand has been published in Science Translational Medicine. By combining Integrum’s OPRA™ Implant System and e-OPRA™ Implant System with revolutionary surgical and engineering advancements and AI algorithms, the user’s intentions were translated into the movement of the bionic fingers.
read moreIntegrum appoints Jeffrey S. Zanni as President, U.S.
Mölndal, Sweden, June 16, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has appointed Jeffrey Zanni as President, U.S., succeeding Thomas Dugan, who has decided to resign from his position.
read moreSVT Documentary; Robothanden
In this documentary, a research participant is followed to get a thought-controlled prosthetic hand. It is life-changing and shows how Integrum’s technology can contribute to the improved function of prosthetics. See documentary
read moreShirley Ryan AbilityLab receives a USD 8.7 million NIH grant to fund clinical trials including Integrum’s e-OPRA Implant System
Mölndal, Sweden, June 8, 2023 – Integrum (publ) (Nasdaq First North Growth Market: INTEG B) today announced that Shirley Ryan AbilityLab – a top-ranked physical medicine and rehabilitation hospital based in Chicago, US – has received a five-year clinical research grant totaling USD 8.7 million from the National Institutes of Health (NIH). The grant will be used to fund two clinical trials evaluating the function of Integrum’s e-OPRA[TM] Implant System. It is anticipated that Integrum will receive up to USD 1.3 million during the program to support the study activities.
read moreYear End Report May 2022 – April 2023: CONTINUING TO BUILD THE COMPANY
read moreIntegrum's e-OPRA™ Implant System highlights in the Swedish national public service television News "Aktuellt," a more extensive coverage is in the Swedish TV show "Ask the Doctor," and there is an article and clip in the Swedish TV Online newsroom.
The Swedish national public service television interviews Tonney Forsberg, an amputee, and Max Ortiz Catalàn, former head of R&D at Integrum, and now a professor in bionics (a mix between biology and electronics). Max talks about the new possibilities opening up by combining osseointegration and AI, a result from the collaboration between Integrum, Chalmers University of […]
read moreMeet Kerstin Caine-Winterberger, among the first occupational therapists in the world specialized in rehabilitation with osseointegration for upper limb patients
In a recent interview, Kerstin Caine-Winterberger described her more than 40 years´ clinical experience in the rehabilitation of upper limb amputees, and the dramatic impact that the introduction of bone-anchored prostheses has made on her patients’ quality of life. As an occupational therapist, Kerstin’s focus has been the rehabilitation of hand injuries and amputations of […]
read moreIntegrum hosted a technical workshop on the clinical advantages of the OPRA™ Implant System and how it helps patients lead more active lives at the AAOP (American Academy of Orthotists and Prosthetists) annual meeting and scientific symposium
May 4th – 7th the AAOP held its annual meeting and scientific symposium (virtually) in New Orleans, Louisiana. During the meeting, Integrum hosted a technical workshop for prosthetists and orthotists from around the world. Presenters during the workshop were Kurt Collier, Certified Prosthetist and VP of Prosthetics at Integrum, Kevin Symms, Certified Orthotist, and amputee […]
read moreIntegrum’s industrial PhD student Alexander Thesleff successfully defends his doctoral thesis “Neuromusculoskeletal interfacing of lower limb prostheses“ at Chalmers University of Technology, Gothenburg, Sweden
On May 27th, Alexander Thesleff received his Ph.D. from the Department of Electrical Engineering, Chalmers University for his research regarding the connection of a leg prosthesis with the skeleton, muscles, and the nerves. Alexander received an Industrial Ph.D. based on his research performed in collaboration with Chalmers and Integrum, for his investigation of the challenges […]
read moreRickard Brånemark interviewed by Innovativa Företag (Innovative Companies)
In their latest issue, Innovativa Företag, a magazine focusing on the most innovative companies in Sweden, interviewed Professor Rickard Brånemark. The magazine is published online, and is distributed in print with Svenska Dagbladet, which is Sweden’s 3rd largest daily newspaper. It reaches approximately half a million readers. During the interview, Professor Brånemark describes the journey […]
read morePer-Ingvar Brånemark, honored by the inauguration of Global Osseointegration Day
May 3rd, 2021, marks the first Global Osseointegration Day, a day which posthumously honors Professor Per-Ingvar Brånemark, who is regarded around the world as the “father” of osseointegration. Global Osseointegration Day will take place every year, on May 3rd, Professor Per-Ingvar Brånemark’s birthday. Read about the event Global Osseointegration Day Professor Brånemark’s pioneering work […]
read moreGöteborgs Posten interviews Ulf Karlsson, one of five persons in Sweden to have received Integrum’s e-OPRA™ Implant System
Göteborgs Posten, the largest newspaper in Western Sweden, interviewed Ulf Karlsson regarding the impact which the unique e-OPRA™ Implant System has had on his life. This unique treatment, developed through a research collaboration between Chalmers University of Technology, Sahlgrenska University Hospital, and Integrum AB, allows Ulf to communicate directly between his brain and his prosthesis. […]
read moreDagens Industri, Invest Talks, interviews Rickard Brånemark, founder and chairman, regarding Integrum’s virtual monopoly in the multi-billion dollar market in the US
With almost half a million daily readers, Dagens Industri is Sweden’s largest financial newspaper. Their independent Investor Relations platform, Invest Talks, which interviews coporate leaders of listed companies, interviewed founder and chairman, Rickard Brånemark regarding the recent PMA (premarket approval) for the OPRA™️ Implant System received from the FDA in the US, and its implications […]
read moreProsthetist shares the dramatic impact of Integrum’s OPRA™ Implant System
Mike Corcoran—Prosthetist specializing in hip disarticulation, hemipelvectomy, and care of wounded warriors Mike Corcoran is the co-founder of Medical Center Orthotics and Prosthetics (MCOP), based in Silver Spring, Maryland, near Washington, D.C. As a prosthetist with 31 years’ experience of practicing prosthetics, and 5 years’ experience of designing and developing artificial limbs to be used […]
read moreIntegrum exhibiting at Hanger Live 2021
Integrum is proud to announce our participation at the Hanger Live, Powered by Purpose, meeting held February 4th-5th, 2021. This virtual educational event allows all 4900 Hanger clinical care providers from across the US to participate and gain valuable insight into the latest developments within O&P (Orthotic and Prosthetic) patient care. Hanger Inc, provides O&P […]
read moreForbes features research with Integrum’s e-OPRA™ Implant System
The digital platform of Forbes Media, Forbes.com, which reaches over 20 million unique visitors each month, featured research from Dr. Max Ortiz Catalán, Chalmers University of Technology, Gothenburg, Sweden observing patients treated with Integrum’s e-OPRA™ Implant System. Latest research on the e-OPRATM Implant System In the Forbes.com article “People with Bionic Hands Can’t Correct […]
read moreDr. Rickard Brånemark and Magnus Niska Interviewed on TV4 Nyhetsmorgon, Saturday, December 19th
On Saturday morning, Dr. Rickard Brånemark, founder of Integrum AB, and Magnus Niska, the first patient in the world treated with Integrum’s revolutionary e-OPRATM Implant System, were interviewed by journalist Jenny Strömstedt, on the very popular TV show, Nyhetsmorgon, on channel 4 in Sweden. During the interview, Dr. Brånemark described this unique and revolutionary treatment, […]
read moreTrevor Noah Podcast: Dr. Max Ortiz Discusses Bionic Limbs and Prosthetic Technology
In the Trevor Noah Podcast episode: Your Robot Brain, Dr. Max Ortiz Catalán explains that the communication gap that once lay between the most advanced prostheses and their users is, thanks to his research and collaboration with Integrum, now bridged. It is now possible to truly connect the brain and the prosthesis, and thereby achieve […]
read moreMagnus Niska of Team e-OPRA won bronze medal at Cybathlon 2020 with Integrum's thought-control bionic arm
Team e-OPRA, a collaborative team made up of professionals from Integrum AB, Chalmers University of Technology, and Sahlgrenska University Hospital, faced fierce competition from all over the world at the Cybathlon 2020. Two athletes (also known as pilots) from Team e-OPRA representing Sweden—Magnus Niska and Tonney Forsberg—participated in the discipline “Power Arm Prosthetic Race“. This […]
read moreTV4 interviews Magnus Niska, as he prepares to compete with his bionic arm in the Cybathlon 2020 Global Edition
Every four years, athletes with disabilities from all over the world participate in Cybathlon, competing in one of several disciplines. This year, due to the global pandemic, athletes or so-called “pilots” gathered online at each team’s home base. Magnus is competing in the discipline “Powered-Arm Prosthesis Race” with Tonney Forsberg. They are guided by Team e-OPRA […]
read moreGiant Step Forward on Artificial Legs
Watch this special segment from CBS Sunday Morning, where Donna and Carol describe how, after receiving osseointegration treatment, their lives have been completely transformed. Where they have previously been confined indoors and condemned to an inactive lifestyle due to their socket prostheses, they are once again able to pursue an active life outdoors; walking, gardening […]
read moreThe Mind-Controlled Prosthetic Arm : Integrum’s e-OPRA™ Implant System at the CYBATHLON 2020
The CYBATHLON is an international multi-sport event in which contestants with physical disabilities compete using the most advanced technical assistance systems. The competition aims to promote and drive the continuous development and exchange of knowledge within assistive technology. Also known as Cyborg Olympics, CYBATHLON is held every four years. The second CYBATHLON takes place on […]
read moreIntegrum presents the OPRA™ Implant System at the American Association of Nurse Life Care Planners, AANLCP
The American Association of Nurse Life Care Planners (AANLCP) is the premier professional member organization of nurses and non-nurses working in the field of life care planning. The AANLCP promotes education, collaboration, exchange of knowledge and research, and the establishment of industry standards in Nurse Life Care Planning. Nurse Life Care Planning in the US […]
read moreBiostock Studio: Integrum has a monopoly situation in the U.S. market
Swedish Integrum AB has developed the only FDA approved method for treating amputees with bone-anchored prostheses. In an interview with Biostock, Rickard Brånemark, founder and Chairman of the Board at Integrum AB, describes the head start that the company has as being alone in the U.S. market for the next 3-5 years; a market which […]
read moreIn Conversation With Biostock:- On Integrum's Leading Position in the Bone-Anchored Prosthesis Industry
In an article published on October 13th, 2020, Biostock interviewed James Sheridan, Head of Sales and Marketing, EMEA, APAC at Integrum AB, and Patrick Treacy, CEO at Onkos Surgical. The article outlines Integrum’s leading position in the bone-anchored prosthetics market, the commercial breakthrough through its framework agreement with the US Military, the Pre-market Approval application […]
read moreIntegrum’s Co-Founder and Chairman of the Board, Professor Rickard Brånemark, interviewed by Biostock
In an article titled ‘Integrum awaits an important milestone on the road to commercial breakthrough‘ published August 2020, Biostock interviews Professor Rickard Brånemark, co-founder and Chairman of the Board. The interview touches upon the history of Integrum with the discovery of Osseointegration and dental implant technology. It visits several milestones for the company, such as […]
read moreIntegrum exhibiting at the Amputee Coalition 2020 National Conference
Join us on August 19-22 at the Amputee Coalition 2020 National Conference! Integrum is happy to announce our participation at the Amputee Coalition virtual 2020 National Conference held between August 19-22. The American Amputee Coalition is a non-profit organization dedicated to enhancing the quality of life for amputees and their families through support, education about […]
read moreIntegrum’s e-OPRA™ Implant System is Restoring Touch in Prosthetic Arms
Advances in robotics are paving the way towards prostheses with functionalities similar to their biological counterparts. While the state-of-the-art prostheses are now capable of mimicking fine movements and grips, the level of intuitive control and sensory feedback individuals with amputation have with their prostheses are still primitive. Researchers recently published the capabilities of our osseointegrated […]
read moreClinical Research Quantifies Loads for Osseointegrated Lower Limb Prostheses
Prosthesis acceptance is a major determinant of people’s quality of life after amputation. Along with factors such as phantom limb pain, misaligned expectations for prosthesis, psychological adjustment and functionality, prosthetic socket issues are a primary reason for prosthesis rejection. Compression and friction forces imposed by the prosthetic socket on the skin of the residual limb […]
read moreReuters features Integrum's e-OPRA™ Implant System
Reuters features Integrum’s e-OPRA™ Implant System The e-OPRA™ Implant System is one of the most advanced prosthetic systems in the world with intuitive control and sensory feedback. The technology is developed upon the OPRA™ Implant System– our bone-anchored prostheses system based on osseointegration. The clinical report demonstrating the long-term performance of the e-OPRA™ Implant system […]
read moreUniversity Medical Center Groningen at the Forefront of Translating Phantom Limb Pain Research into Clinical Care with Neuromotus™
The University Medical Center Groningen As one of the largest hospitals in the Netherlands and the largest employer in the Northern Netherlands, the University Medical Center Groningen (UMCG) focuses on care, education, training, and research. The UMCG not only provides patient-centered care but also aims to conduct revolutionary scientific and educational research on healthy ageing to build the […]
read moreBo Håkansson, a pioneer in osseointegration research, rewarded honorary doctorate at the Sahlgrenska Academy.
Bo Håkansson is a professor of Electrical Engineering at the Chalmers University of Technology. He is the pioneering researcher in bone-anchored hearing implants. His work resulted in the translation and development of commercially available osseointegrated hearing aids that have positively impacted the lives of several thousands of people worldwide. The appointment by the Board of […]
read moreOPRA™ Implant System – Transforming the World of Prosthetics
ABC 12 News features Osseointegration with the OPRA™ Implant System ABC 12 News, a news channel in Michigan, featured the OPRA™ Implant System and the technology of Osseointegration on their segment HealthSource. Watch the video here. They interviewed Munya Mahiya, who recently shared his story on WMC5 Action News, highlighting Osseointegration and the OPRA™ Implant […]
read moreIntegrum and Onkos Surgical hold second educational seminar on Osseointegration
Integrum and Onkos Surgical hosted their second online educational symposium recently on the surgical and prosthetic technologies used with the OPRA™ Implant System. The symposium was attended by 30 participants from 15 institutions. We thank all the participants and look forward to continued collaborative work The collaboration between Integrum and Onkos Surgical is focused on […]
read moreJob Opening: Head of Sales and Marketing EMEA
Integrum AB is seeking to hire an executive to lead its Sales and Marketing organization. The individual will oversee Integrum’s product portfolio: OPRATM Implant System – a revolutionary surgical technology that allows amputees to be set free from the confines of a traditional socket-based prosthesis and Neuromotus – an innovative solution for the treatment of […]
read moree-OPRA™ recipient shares his perspective on TV4 news
The Ideal Replacement for a Biological Hand The conclusions of the clinical study on the efficacy and performance of the e-OPRA™ system was published recently in the New England Journal of Medicine. One of the recipients of the e-OPRA™ system. Rickard Normark, shared his perspective on TV 4, a Swedish news channel. Watch the interview […]
read moreA Near Bionic Prosthetic-The OPRA™ Implant System
A Near Bionic Prosthetic Munya Mahiya, a UC Berkeley Alumnus and a wheelchair basketball player for the Golden State Road Warriors, has recently shared his story and postoperative experience with the OPRA™ Implant System on WMC Action News 5. The OPRA Implant system is a bone-anchored prosthesis system that allows the prosthesis to be skeletally […]
read moreOnkos Surgical & Integrum Co-Hosts Educational Session On Osseointegration
With the spread of the pandemic and consequent restrictions on traveling the American Academy of Orthopaedic Surgeons Annual Meet 2020 in Florida was canceled where Integrum and Onkos Surgical had planned their inaugural presentation after the partnership announcement in January 2020. The collaboration between Integrum and Onkos Surgical is focused on expanding the US market […]
read moreDr.Max Ortiz Catalan receives the Chalmers Foundation Award 2020
Dr. Max Ortiz Catalan receives the Chalmers Foundation Award for 2020 for his work on natural control of prostheses through osseointegrated implants. CHALMERS FOUNDATION The Foundation’s motivation for the award is as follows: “The Chalmers Foundation was formed in 1994, with the task of supporting Chalmers to carry out research and education at a high […]
read moreDr. Brånemark to present at University of Maryland
Dr.Brånemark will present a Seminal Research lecture on Osseointegration at the University of Maryland on 28th February. He will share the groundbreaking advances within osseointegration and limb restoration as well as the latest research. Despite the advances in prosthesis and sockets, there is a high rejection rate of socket prosthesis among people with amputation. For […]
read moreMilestones in Amputation Care at University Medical Center Göttingen
University Medicine Göttingen(UMG) positions itself at the forefront of orthopedic surgery in Germany with the completion of its first Osseointegrated and Targeted Muscle Reinnervation (TMR) surgery last year. Osseointegration for amputees refers to the anchoring the prosthesis directly through the bone. This treatment is becoming a widely acceptable and beneficial alternative for those who have […]
read moreAlfred Hospital-Establishing Holistic Amputee Care Management in Australia
In October 2019, Alfred Hospital conducted their fourth workshop on Osseointegration for Bone Anchored prosthesis with the OPRA Implant system and Target Muscle Reinnervation (TMR) at the Regional Medical Australian and New Zealand Society (RMANZ). Pioneering Osseointegration in Australia The Alfred Hospital is the largest and most active Trauma Service in Australasia. They treat over […]
read moreHenry Wallman 2019 Award Cermony
In June 2019, the Stiftelsen Medicin och Teknik at Chalmers announced Dr. Rickard Brånemark, Dr. Max Ortiz Catalan and Kerstin Hagberg as the receipients of the 2019 Henry Wallman Award. The award recognizes their work within osseointegrated neural controlled prosthetics (e-OPRA). Our press release published 26 June 2019 describes more about the the work that […]
read moreEvent Recap: Osseointegration at 2019 NEAAOP Conference
Developments in Osseointegration The benefits of osseointegration for both upper and lower limb amputees has been well recognized and documented in numerous peer reviewed clinical studies. In June of 2015 the FDA provided an HDE approval (Humanitarian Device Exception) for use of the OPRA System (Osseointegrated Prosthesis for Rehabilitation of Amputees) for transfemoral amputees. Work […]
read moreInside Walter Reed: The Future of Prosthetics
NBC4 News aired a segment on ‘Inside Walter Reed:The Future of Prosthetics‘ on October 8th’ 2019. The program features the OPRA Implant System from Integrum. News4’s Doreen Gentzler talks about her visit to Walter Reed National Military Medical Center at Bethesda, Washington. During the visit, she learned about the clinical trial evaluating Osseointegration as a […]
read moreUpcoming Event: Dr. Ortiz holding Keynote Lecture at ISPO World Congress 2019
International Society for Prosthetics and Orthotics (ISPO) Kobe, Hyogo Japan 5-8th October 2019 Kyobe, Hyogo Japan is hosting the 17th International Society for Prosthetics and Orthotics (ISPO) World Congress between 5-8th October 2019. ISPO is a global non-profit organization working towards improving the quality of life for people with reduced mobility. This is done by […]
read moreIntegrum on 'Voice of Industry'-ORTHOWORLD
ORTHOWORLD® is a provider of strategic intelligence focussed on the global orthopaedic market. Their mission is to help orthopaedic companies and individuals improve their performance. They featured an interview with Magnus René on the success of the OPRA™ osseointegrated prosthetic implant system. Magnus René is the former President and CEO of Arcam and member of […]
read moreUpcoming Event: OPRA Insight Forum Series: Chapter Orlando
The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the limb loss community about Osseointegration. The forums are designed to provide a broad perspective on Osseointegration and specifically the OPRA Implant System. A review of the acceptance criteria for consideration, brief […]
read moreUpcoming Event: OPRA™ Insight Forum Series: Chapter Boston
The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the limb loss community about Osseointegration. The forums are designed to provide a broad perspective on Osseointegration and specifically the OPRA Implant System. A review of the acceptance criteria for consideration, brief […]
read morePatient completes 20 year check up with OPRA™ Implant System
Erik Ax, 79 years old, is one of the earliest recipients of the OPRA™ Implant System. Erik is an above-knee amputee who was having several problems with his prosthetic socket.As a result, he sought out Integrum to receive an osseointegrated bone-anchored prosthesis. He had his osseointegration surgery in 1999 and is now having his implant […]
read moreUpcoming Event: Clinical Assessment for Osseointegration Patients in London, UK
London International Patient Services (LIPS) is hosting a clinical assessment session with Mr.Culpan and Prof. Brånemark on Sept 13, 2019. At this session, Prosthesists or Orthosists with patients interested in Osseointegration and amputees will have the opportunity to get a clinical assessement for osseointegration with the OPRA Implant System. The session will be held at […]
read moreUpcoming Event: 20th Annual Meeting of ISOLS, 2019
Athens, Greece will be hosting the 20th Annual Meeting of International Society of Limb Salvage (ISOLS). The ISOLS is a platform where experts in the field of musculoskeletal oncology and limb salvage techniques come together to promote intellectual exchange in research, surgical techniques, education and clinical practice in the discipline. Dr. Rickard Brånemark will be […]
read moreCelebrating 10 years of Osseointegration in Chile. Pioneering Osseointegration in Latin America.
On Aug 20th, Hospital del Trabajador-Chile hosted the Congress of Osseointegration 2019 in commemoration of 10 years of Osseointegration in Chile. Hospital del Trabajador are the pioneers in the region and the only center providing osseointegration in Latin America. Over 90 participants from a mixed population of surgeons, healthcare providers, physiotherapists, occupational therapists and amputees […]
read moreINTEGRUM TO INAUGURATE OPRA INSIGHT FORUM SERIES
In conjunction with the company’s ongoing expansion in the US, Integrum will inaugurate the OPRA Insight Forum Series with its first chapter in Charlotte, North Carolina, USA on August 27TH, 2019. The OPRA Insight Forum Series is a set of outreach programs hosted by Integrum held across the U.S. to help educate and inform the […]
read moreCelebrating 10 years of Osseointegration in Chile . Pioneering Osseointegration in Latin America.
We are glad to celebrate 10 years of experience in osseointegration with our collaboration team in Chile during the Congress of Osseointegration in Hospital del Trabajador- Chile, which will be held on August 20, 2019. The convention will provide healthcare providers, patients and the community with information on osseointegration with the OPRA Implant System, its […]
read moreCongratulations to UCSF on being ranked among Best Hospitals in USA.
US News recognizes UCSF Medical Center as one the leading hospitals in the country with 10 departments in the top 10 centers nationwide in their U.S. News & World Report’s 2019-2020. The orthopaedics department has been ranked 4th nationwide. Integrum congratulates UCSF on their continued recognition as one of the most prestigious hospitals in the […]
read moreBest Wishes for the Summer Holidays!
read moreCongratulations Dr Enzo Mastinu!
We are proud to announce that our colleague Enzo Mastinu has successfully defended his PhD thesis, “Towards clinically viable neuromuscular control of bone-anchored prosthetic arms with sensory feedback” at Chalmers University of Technology. Dr. Mastinu has pursued his PhD in a joint collaboration between Integrum AB and Chalmers University of Technology, developing an embedded system for intuitive control of a […]
read moreMeet Integrum at FEESH,17-21st of June in Berlin, Germany!
We are pleased to announce that Integrum will participate at the FEESH meeting 17-21 st of June 2019 in Berlin, Germany. Integrum will be present in the booth at Pohlig GmbH. During the meeting the technology of osseintegration for finger/thumb and arms will be shown. In January 2019 a new study was published to be […]
read moreCOME VISIT US AT VITALIS 2019 Integrum will be presenting at Vitalis (Booth B06:71)
Vitalis is the largest eHealth event in Scandinavia. The event is visited by many key individuals, organizations and companies operating in the Nordic countries. A growing number of delegates from outside the Nordics are also attending.
read moreProf R Brånemark is a selected speaker and will give a lecture at Klinikum der Universität München, Germany, 18th of September.
Next week, 18th of September 2018, Prof Rickard Brånemark who is a selected speaker at the Klinikum der Universität München, will give a lecture on Osseointegrated Implants in prosthetic extremity reconstructions- Interfacing in the 21st century. Flyer_SL_Branemark_2018-07-11
read moreRick Cicero, transfemoral and transhumeral amputee and recipient of Integrum’s OPRA Implant System.
Rick Cicero KVOA News 4 Tucson AZ July 16th, 2018 Rick Cicero, transfemoral and transhumeral amputee and recipient of Integrum’s OPRA system at both levels shares his life changing experiences on the local news channel in Tucson, Arizona during the Annual Amputee Coalition Conference. He is providing a presentation to the rehabilitation specialist […]
read moreAssociation of Orthotist and Prosthetist of America
The 2018 National Assembly will be held September 26-29 in Vancouver, BC, Canada—An expected 2,500 attendees from over 40 different countries are expected to attend. A larger booth, #1212, with two OPRA patients present will increase our presence and help to strengthen the brand. Lastly, Dr. Branemark’s presentation during the Future Possibilities in Amputation Surgery […]
read moreMeet us at 2nd International Symposium on Innovations in Amputation Surgery and Prosthetic Technologies meeting (IASPT) May 9-12th 2018 in Vienna!
We are pleased to announce that Integrum will participate at the 2nd International Symposium on Innovations in Amputation Surgery and Prosthetic Technologies meeting (IASPT) May 9-12th 2018 in Vienna, Austria. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in our booth. […]
read moreMeet us at EMSOS 9-11 th of May in Amsterdam!
Meet us at EMSOS 9-11 th of May in Amsterdam! We are pleased to announce that Integrum will participate at the EMSOS (European Musculo-Skeletal Oncology Society) meeting 2018 May 10-11 in Amsterdam, Netherlands. Please visit us and meet with some of Integrum’s product users and Integrum staff. You are very welcome to find us in booth 2.
read moreOPRA™ bone anchored prosthesis now available in London
The unique OPRA™ Implant System from Integrum, who improves the quality of life for patients by eliminating the need for a conventional socket prosthesis, is now provided by London International Patient Services (LIPS) your connection to London’s top consultants. For more information please click on this link: IntegrumLIPS
read moreMeet us at the OTWorld 15th-18th of May 2018 in Leipzig!
We are pleased to announce that Integrum will participate at the OTWorld 2018 May March 15-18th in Leipzig. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in booth D01b Hall 5. During the OTWorld meeting Integrum will also invite for […]
read moreMeet us at the AAOS 2018 Annual Meeting!
We are pleased to announce that Integrum will participate at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting March 6-10 in New Orleans, Louisiana, USA. Please visit us and meet with some of Integrums product users, medical professionals and Integrum staff. You are very welcome to find us in booth 1013. Meeting Location: […]
read moreUS Army Soldiers are fitted with Integrum’s OPRA Implant System
Integrums collaboration with the US Department of Defense is showing good progress and several patients have started the rehabilitation phase. The osseointegration program is led by the work of Navy Commander (Dr.) Jonathan Forsberg and Army Lieutenant colonel (Dr.) Kyle Potter. Please click on the link to experience some of the great achievements https://www.youtube.com/watch?v=eS4O99lLgrY&feature=youtu.be […]
read moreIntegrum is included in the magazine inMotion for the limb loss community
The award-winning publication inMotion is written by healthcare professionals, leaders in the limb loss community and those affected by limb loss. Integrum is proud to be part in the inMotion magazine and hope that more individuals with limb loss will recognize the benefits of bone anchored prosthesis. Please klick on the link for the full […]
read moreIntegrum was recognized by the French President Emmanuel Macron and Stefan Löfven
Integrum had the honor to meet the President of France and the Swedish Prime Minister this Friday evening. Very honorable that Integrum is recognized at this event and we hope that it will enable us to reach out to more people in France. Check out the last 6 minutes of the video link: https://www.facebook.com/EmmanuelMacron/videos/2062784580620784/
read more2-day instructional course in osseointegration
Save the date 15-16th Nov 2017 Integrum invites medical professionals to participate in a 2-day instructional course for the OPRA Implant System for thumb/finger, humerus and femur in November 2017. The course will give the professionals an introduction to osseointegration and the OPRA Implant System. The attendees will have the opportunity to meet with experienced […]
read moreThe US Department of Defense offers amputees a revolutionary new option in prosthesis
<!–Notes ACF –> Integrums collaboration with the US Department of Defense has good progress and some patients have already initiated the treatment using Integrums OPRA Implant System. The osseointegration program at Walter Reed Walter Reed National Military Medical Center (WRNMMC) began in 2016. The osseointegration program is led by the work of Navy Cmdr. (Dr.) […]
read moreIntegrum's first delivery to Ottobock in the United States
The first delivery of Integrum prosthetic components to Ottobock has been carried out in the United States. This marks the start of Integrum’s collaboration with Ottobock Healthcare. The order represents a strategically important milestone since Ottobock can start to sell & market Integrum’s products on the US market. “We are very proud to collaborate with […]
read moreNasdaq Stockholm welcomes Integrum to First North
Nasdaq (Nasdaq: NDAQ) announces that the trading in Integrum AB’s shares (short name: INTEG B) commenced today on Nasdaq First North in Stockholm. Please read more here
read moreWinner of the Blatchford Award 2017
Integrum collaborators have been awarded for outstanding record of innovative achievement in the field of prosthetics and/or orthotics. The Blatchford Award 2017 has been presented to the multidisciplinary team of surgeons, physiotherapists, occupational therapists, and prosthetists from Sahlgrenska University Hospital (SUH), as well as researchers from Chalmers University of Technology (CTH) and University of Gothenburg […]
read moreNasdaq First North IPO May 15th
Integrum has talking the steps to be a listed company on Nasdaq First North. We have reached several milestones in the listing process and the date is set to be May 15 as the introduction date. This will enable several advantages for Integrum and we will be able to provide additional resources for development, marketing […]
read moreIntegrum and Ottobock Partner for the Benefit of Amputees
Integrum has entered a collaboration with Ottobock in the field of osseointegration regarding distribution of prosthetic connection elements related to Integrum’s OPRA implant system. Integrum is thrilled to collaborate with Ottobock, the market leader in prosthetics, to distribute Integrum’s prosthetic components in the US. This is a major step forward in developing Integrums presence in […]
read moreIntegrum surgical course in San Diego, March 12-13, 2017
The University of California San Francisco (UCSF) and the Orthopaedic Surgical Osseointegration Society (OSOS) are arranging the 7th international conference about Advances in Orthopaedic Osseointegration. Several Integrum co-workers will participate and share some of our latest developments. Integrum will arrange a surgical course at the conference. Please read more here
read moreA new stronger OPRA Implant System is launched
Integrum is introducing the OPRA Implant System Platform G to be used for transfemoral patients. The new platform is CE labeled and approved by the FDA and will be available in January 2017. The OPRA Implant System Platform G improves the mechanical performance of the system, simplifies the surgical procedure and enhances osseointegration. Please contact […]
read moreA revolutionary phantom limb pain treatment
Neuromotus is a revolutionizing technology to relieve Phantom Limb Pain. The technology has been proven in a clinical trial with good results. The results have recently been published in the medical journal The Lancet. The technology is in the final stage of development. Please read more at our new product website Neuromotus.se and sign up […]
read moreUCSF Medical Center performs Osseointegration crowdfunding campaign
UCSF Medical Center is planning to treat several Transfemural (above the knee) patients on a yearly basis. Apart from hospital expenses, patients traveling from across the nation will have to find resources to cover the cost of lodging and travel in order to have the first clinical screening, as well as surgery and aftercare. UCSF […]
read moreIntegrum’s Research Director, Dr. Max Ortiz Catalán is the winner of the 14th Annual Delsys Prize
Dr. Max Ortiz Catalán winning proposal, titled “Myoelectric pattern recognition and augmented reality for the treatment of Phantom Limb Pain”, was selected from a field of 134 entries from 29 countries. The entries represented a remarkably broad range of interests in diverse areas as Biomechanics, Exercise Physiology, Signal Processing, Facial EMG, Robotics, Rehabilitation, and various […]
read moreSweden wins medal in the Cybathlon competition, “cyborg Olympics”, at the Swiss Arena in Zürich
The first recipient of our osseointegration and neural control technology competed on 8 October in the Cybathlon, an event aimed at pushing the technological boundaries to reduce disability. More than 8,000 spectators and 700 journalists covered this initial event. Despite being the only participant with an above-elbow amputation, a disadvantage when competing against below-elbow-amputees, the […]
read moreThe first US surgery has successfully been performed at UCSF
UCSF Medical Center in San Francisco is the first U.S. center to proceed with an OPRA program. This unique program gives amputees new hope for better prosthesis. The historic first U.S. surgery with the Integrum OPRA System took place last week. The patient receiving the implant is a 54-year-old man who lost most of his right leg due to […]
read moreKerstin Hagberg in the latest issue of “Fysioterapi”
Physiotherapist Kerstin Hagberg, associate professor at the Centre of Orthopaedic Osseointegration (COO) at Sahlgrenska University Hospital, is in the latest issue of the Swedish magazine “Fysioterapi”. In the article, you can read about Kerstin’s work and how the OPRA Implant system has change the life for a young Swedish man. Read the article here (Swedish)
read moreDr. Brånemark featured speaker at IAA Conference
The founder of Integrum, Dr. Rickard Brånemark , is one of the featured speakers at the 30th Annual meeting of the International Anaplastology Association to be held June 1-4, 2016 in Dallas/Fort Worth, Texas. Take the opportunity to listen to Dr. Brånemark and his presentation “Osseointegration for Orthopedic Applications” on 2 June at 2.05 pm. Read […]
read moreNews report
ABC 7 News have done a news report about the OPRA Implant System that is currently being tested at the University of California, San Francisco. The report can be read here
read moreOrthotic and Prosthetic Innovation & Technology Symposium
Dr. Rickard Brånemark, founder of Integrum, is one of the featured speakers at the 6th Orthotic and Prosthetic Innovation & Technology Symposium which is held on the 6th of November in the Milberry Union Event & Meeting Center in San Francisco. You can read more about the symposium here
read moreArticle in Göteborgs-Posten
The Swedish Newspaper Göteborgs-Posten, the biggest daily morning paper in the west of Sweden, published an article about Integrum. The article describes how Integrum will enter the US market and also briefly describes conventional products compared to bone anchored prostheses. The article can be read here (in Swedish)
read moreArticle in Dagens Industri
The Swedish newspaper Dagens industri, Scandinavia’s largest business newspaper, has published an article about Integrum. The article relates to Integrum being the first company in the world with bone anchored prosthesis to be approved by the FDA for use in the U.S. The article can be read here (in Swedish)
read moreThe OPRA Implant System is FDA approved
The U.S. Food and Drug Administration (FDA) has of today, July 16th 2015, announced that the humanitarian device exemption (HDE) for Integrum´s OPRA Implant System is approved. The approval provides an unprecedented opportunity to improve the life for several thousands of individuals living with limb loss in the United States. Integrum is the first company […]
read moreSwedish Medtech week
Integrum was part of the Swedish Medtech week hosted by the Association for Medical Technology in Sweden. Integrum presented the company and demonstrated some of the latest research. This was an event for national and regional officials and politicians aiming to raise awareness and create a conversation about medical technology. You can read more about […]
read moreConference of the International Graphonomics Society
Dr. Max Ortiz Catalan from Integrum will give a keynote speech at the 17th Conference of the International Graphonomics Society on Monday 22th of June. You can read more about it here
read moreA big thank you
A big thank you to everyone who participated in the Prosthetic course last week. We appreciate the feedback and it was nice to see everyone.
read morethe Shanghai Symposium on Neural-Machine Interfacing
Dr. Max Ortiz Catalan from Integrum will be giving a talk at the Shanghai Symposium on Neural-Machine Interfacing on June 16th. The talk will be about his neuromuscular interface that allows for mind controlled prosthetics that is based on the OPRA Implant System
read moreThe Centre of Advanced Reconstruction of Extremities
The Centre of Advanced Reconstruction of Extremities (C.A.R.E.) at Sahlgrenska University Hospital is inaugurated on Friday the 22th of May. Integrum will be present as will some of the patients using the OPRA system.
read moreMeet us at AAOS Annual Meeting!
We are pleased to announce that Integrum will participate at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas, March 25-27, 2015. You are very welcome to find us in booth number 664. See more here.
read moreGöteborgs-Posten
The Swedish newspaper Göteborgs-Posten, has a piece on a patient treated with the OPRA Implant System. The treatment has helped the patient return to his job as an optician and has improved his quality of life. The piece can be read here (in Swedish).
read morePresentation
CEO of Integrum and associate professor at Sahlgrenska University Hospital, Dr. Rickard Brånemark and Dr. Max Ortiz Catalan presented their work in mind-controlled prosthetics to the Swedish Minister of Enterprise, Mikael Damberg. The Swedish news paper, Dagens Industri, did a report that can be read here (In Swedish, requires subscription, but a free try-out period is available)
read moreWatch the TEDxGöteborg-talk
In November, Dr. Max Ortiz Catalan from Integrum gave a talk at TEDxGöteborg about his mind controlled prosthetics that are based on the OPRA Implant System. The talk can be watched here
read moreWatch the Spanish talkshow
Dr. Max Ortiz Catalan from Integrum participated in the Spanish talkshow El Hormiguero together with 2 patients. The show can be streamed here (in Spanish). Integrums effort into mind controlled prosthetics is considered the 7th most important research project by the Swedish Dagens Medicin. Their report can be read here (in Swedish).
read moreParticipating in the Spanish talkshow El Hormiguero
Dr. Max Ortiz Catalan from Integrum will participate in the Spanish talkshow El Hormiguero together with Magnus Niska, who is the first patient using OPRA with neuromuscular electrodes and Irene Villa, who is a bilateral amputee using the OPRA implant system. The program is broadcasted on Spanish Antena 3 TV the 10th of December at […]
read moreInterview with Magnus Niska
Magnus Niska, the first patient using OPRA with neuromuscular electrodes, was interviewed in the Swedish talkshow “Malou efter tio”. The interview can be seen here (in Swedish).
read moreTEDxGöteborg
Dr. Max Ortiz Catalan from Integrum will give a talk at TEDxGöteborg the 18th of November about his mind controlled prosthetics that are based on the OPRA implant system. More information about the talk can be found here
read moreInterview with Dr. Rickard Brånemark
CEO of Integrum and associate professor at Sahlgrenska University Hospital, Dr. Rickard Brånemark, is interviewed by Reuters about the mind-controlled prosthetic arm, that has been made possible with the next generation of the OPRA system. The report can be seen here.
read moreThe first patient using OPRA™ with implanted neuromuscular interfaces is revealed.
The future for the OPRA™ system is presented today, as the first patient using OPRA™ with implanted neuromuscular interfaces is revealed. The system has been used by the patient since January 2013. This breakthrough is the result of a collaboration between Integrum, Chalmers University of Technology and Sahlgrenska University Hospital. The official press release can […]
read moreLecture by Max Jair Ortiz Catalan
Max Jair Ortiz Catalan from Integrum will give a short lecture on future control of arm and leg prosthetics at the National Life Science Day. The event takes place at Skogshem & Wijk, Lidingö on the 30th of September and the lecture will be at 11:20. Read more about it here.
read moreStudy from Chalmers University of Technology
In February this year, a study from Chalmers University of Technology, that was supported by Integrum, that demonstrated a novel treatment for phantom limb pain (PLP) was published. The treatment successfully reduced the pain levels for a chronic PLP patient, for whom no other treatments had been successful. A multi-centre clinical trial verifying the results from this […]
read moreLecture by Dr. Todd Kuiken
Dr. Todd Kuiken from the Rehabilitation Institute of Chicago is giving a lecture on Developing Neural Interfaces for Robotic Prostheses at Chalmers Wednesday the 11th of June at 15:00-16:00. The lecture is taking place at the EC-room, EDIT-building at Hörsalsvägen 11
read moreVetenskapsfestivalen
Researchers from Integrum will participate in Vetenskapsfestivalen (The Science Festival) in Gothenburg Friday the 9th of May to present research in naturally controlled prosthetics. Research engineers Morten Bak Kristoffersen and Alejandra Zepeda will have a presentation followed by a 2-hour demonstration at 13:00 in Nordstan and research engineer Max Ortiz Catalan will give a lecture at 19:30 […]
read moreVinnova
Integrum just received 5 out of 65 million SEK for innovative small and medium sized companies from Vinnova. The funding is for further development in osseointegrated nerve and muscle controlled prosthetics with sensory feedback. The press release from Vinnova can be read here (in Swedish)
read morePresentation
Dr. Örjan Berlin will do a oral presentation titeled An osseointegrated percutaneous prosthetic system for the treatment of patients with transfemoral amputation: Results from the OPRA technique at EMSOS 2014 Friday the 23rd of Maj.
read moreBjörn Rydevik talks about osseointegrated amputation prostheses
On Friday March 7, at the Swedish Embassy in Tokyo, Professor Björn Rydevik will talk about osseointegrated amputation prostheses. Click here for more information.
read moreA new study
A new study from Chalmers University of Technology and the Center of Orthopaedic Osseointegration on the treatment of phantom limb pain (PLP) has been published today. The study presents a novel treatment that has successfully reduced the pain levels for a chronic PLP patient for whom other treatments have not worked. The study has been […]
read moreProspective clinical study
The first prospective clinical study of 51 patients treated with an osseointegrated prosthetic system for transfemoral amputation is published in the Bone and Joint Journal. The study presents a cumulative survival rate of 92% at two years combined with enhanced prosthetic use and mobility, fewer problems and improved quality of life, which supports the ‘revolutionary […]
read moreThe main feature
Christoffer Lindhe, who is a trilateral amputee with two fixtures osseointegrated into the bones, is the main feature in the newest edition of Ingenjören (eng. The Engineer). The article is about his accident, life and his work to bring his own prosthetic foot to the market. The article is available here (pdf, page 25).
read moreA new team
The new team at Centro Hospitalar do Porto in Portugal has performed their first surgery with the OPRA Implant System. We welcome Dr. Cantista, Dr. Cardoso, Dr. Oliviera and their team and look forward to our future collaboration.
read more